|12/04/16||Global Blood Therapeutics Announces New Long-Term Clinical Data from Ongoing Phase 1/2 Trial of GBT440 in Sickle Cell Disease at ASH|
|--Results Showed GBT440 Treatment Led to Rapid, Significant, Profound and Durable Reduction in Hemolysis and Sickled Cells in All Patients Treated for Up to Six Months--
--Company to Host Webcast Tomorrow at 12:15 p.m. PT to Discuss Data--
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the presentation of results from its ongoing Phase 1/2 GBT440-001 study that further support the safety and efficacy profile o... |
|11/30/16||Global Blood Therapeutics Announces Upcoming Investor Webcast to Review GBT440 Data Being Presented at ASH that Support Sickle Cell Disease Program|
|SOUTH SAN FRANCISCO, Calif., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), today announced that it will host an investor webcast on Monday, December 5, 2016, at 12:15 p.m. PT/3:15 p.m. ET, to review new data being presented at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition Conference in San Diego that support its GBT440 program in sickle cell disease (SCD). The investor event will feature members of GBT’s management team an... |
|11/30/16||Global Blood Therapeutics Announces GBT440 Granted Orphan Drug Designation in Europe for Treatment of Sickle Cell Disease|
|SOUTH SAN FRANCISCO, Calif., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), today announced that the European Commission (EC), acting on a positive recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), has designated GBT440 as an orphan medicinal product for the treatment of sickle cell disease (SCD).
"Receiving orphan designation from the EC marks a significant milestone both for the SCD co... |
|11/28/16||Global Blood Therapeutics Announces Initiation of Phase 2a Trial of GBT440 in Idiopathic Pulmonary Fibrosis (IPF)|
|SOUTH SAN FRANCISCO, Calif., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), today announced enrollment of the first patient in ZEPHYR, a Phase 2a clinical trial evaluating the safety and efficacy of GBT440 for the treatment of hypoxemia in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest.
Hypoxemia (abnormally low levels of oxygen in the blood) is a common finding in IPF, is the underlying cause for patients’ sym... |